(Updated - November 8, 2023 7:04 AM EST)

Biogen (NASDAQ: BIIB) reported Q3 EPS of $4.36, $0.37 better than the analyst estimate of $3.99. Revenue for the quarter came in at $2.53 billion versus the consensus estimate of $2.39 billion.

GUIDANCE:

Biogen sees FY2023 EPS of $14.50-$15.00, saw $15.00-16.00,

• Reflecting ~$0.75 of dilution from Reata acquisition which closed September 26, 2023

For earnings history and earnings-related data on Biogen (BIIB) click here.

Earnings Guidance Hot Earnings Hot Guidance